Stock Ratings | Morgan Stanley maintained its "neutral" rating on Palantir Technologies (PLTR) and raised its price target from $155 to $205.
Syndax Pharmaceuticals Inc SNDX | 23.36 | +3.91% |
Benitec Biopharma Inc BNTC | 10.65 | +5.86% |
LIQUIDIA TECHNOLOGIES INC LQDA | 37.74 | +7.28% |
Can-Fite BioPharma Ltd. Sponsored ADR CANF | 3.10 | +2.99% |
IonQ, Inc. IONQ | 28.83 | +8.42% |
The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.
Risk warning:
Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.
Today's key assessments and concerns
UBS: Maintaining Syndax Pharmaceuticals' ( Syndax Pharmaceuticals Inc(SNDX.US) ) rating at "Buy", while raising the target price from $35 to $38.
HC Wainwright & Co.: Maintaining a "Buy" rating on Benitec Biopharma ( Benitec Biopharma Limited Sponsored ADR(BNTC.US) ), while raising the target price from $28 to $35.
Needham: Maintaining a "buy" rating on Liquidia ( LIQUIDIA TECHNOLOGIES INC(LQDA.US) ), while raising the price target from $36 to $52.
HC Wainwright & Co.: Initial rating for Can-Fite BioPharma Ltd. ( Can-Fite BioPharma Ltd. Sponsored ADR(CANF.US) ) at "Buy", with a target price of $2.5.
Morgan Stanley: Maintaining IonQ's rating ( IonQ(IONQ.US) ) at "Market Weight", while raising the price target from $32 to $58.
| The symbol | Classification | Target price | Current price | Percentage of potential increase/decrease | (Classification) Agency |
| Syndax Pharmaceuticals Inc(SNDX.US) | to lift | $38.0 | $15.35 | 147.56% | UBS |
| Benitec Biopharma Limited Sponsored ADR(BNTC.US) | to lift | $35.0 | $15.71 | 122.79% | HC Wainwright & Co. |
| LIQUIDIA TECHNOLOGIES INC(LQDA.US) | to lift | $52.0 | $27.91 | 86.31% | Needham |
| Pyxis Oncology, Inc.(PYXS.US) | to lift | $7.0 | $3.9 | 79.49% | Guggenheim |
| LIQUIDIA TECHNOLOGIES INC(LQDA.US) | to lift | $50.0 | $27.91 | 79.15% | HC Wainwright & Co. |
| Can-Fite BioPharma Ltd. Sponsored ADR(CANF.US) | Initial classification | $2.5 | $0.41 | 509.76% | HC Wainwright & Co. |
| THL Credit Inc 6 3/4 % Notes 2014-15.11.21 Sr(TCRX.US) | cut | $6.0 | $1.12 | 435.71% | Needham |
| Sable Offshore(SOC.US) | cut | $20.0 | $5.9 | 238.98% | Benchmark |
| Karyopharm Therapeutics, Inc.(KPTI.US) | cut | $19.0 | $5.65 | 236.28% | RBC Capital |
| BioCryst Pharmaceuticals, Inc.(BCRX.US) | cut | $18.0 | $6.76 | 166.27% | Needham |
comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)
Lifting
Mizuho: Maintaining Amazon's ( Amazon.com, Inc.(AMZN.US) ) rating at "Outperforming the Market," while raising the target price from $300 to $315.
UBS: Maintaining a "neutral" rating on Caterpillar ( Caterpillar Inc.(CAT.US) , while raising the price target from $506 to $581.
Benchmark: Maintaining DoorDash's DoorDash(DASH.US) "buy" rating, while raising the price target from $315 to $320.
Benchmark: Maintaining a "Buy" rating on Grab Holdings ( Grab(GRAB.US) , while raising the target price from $6 to $7.
B of A Securities: Maintaining Hims & Hers Health's ( Hims & Hers Health(HIMS.US) ) rating at "Underperforming the Market", while raising the price target from $28 to $32.
Tigress Financial: Maintaining a "buy" rating on Intel Intel Corporation(INTC.US) ) stock, while raising the price target from $45 to $52.
Morgan Stanley: Maintaining IonQ's rating ( IonQ(IONQ.US) ) at "Market Weight", while raising the price target from $32 to $58.
Piper Sandler: Maintaining Ionis Pharmaceuticals, Inc.(IONS.US) Pharmaceuticals' rating at "Overweight", while raising the target price from $70 to $77.
Morgan Stanley: Maintaining Microchip Technology Incorporated(MCHP.US) Technology's rating at "Market-Similar Weight", while raising the price target from $63 to $68.
Citizens: Maintaining MongoDB's ( MONGODB(MDB.US) ) rating at "Outperforming the Market," while raising the price target from $375 to $435.
Truist Securities: Maintaining a "buy" rating on MongoDB MONGODB(MDB.US) , while raising the price target from $375 to $400.
BMO Capital: Maintaining MongoDB's ( MONGODB(MDB.US) ) rating at "Outperforming the Market", while raising the price target from $365 to $415.
UBS: Maintaining a "neutral" rating for Children's Place ( Children's Place(PLCE.US) ), while raising the price target from $7 to $8.
Cantor Fitzgerald: Maintaining a "neutral" rating on Palantir Technologies Palantir(PLTR.US) , while raising the price target from $155 to $198.
Baird: Maintaining a "neutral" rating on Palantir Technologies Palantir(PLTR.US) , while raising the price target from $170 to $200 .
Goldman Sachs: Maintaining its rating on Palantir Technologies Palantir(PLTR.US) at "neutral", while raising its price target from $141 to $188.
UBS: Maintaining a "neutral" rating on Palantir Technologies Palantir(PLTR.US) , while raising the price target from $165 to $205.
RBC Capital: Maintaining Palantir Technologies' (PLTR) rating at "Underperforming Market", while raising the price target from $45 to $50.
DA Davidson: Maintaining a "neutral" rating on Palantir Technologies (PLTR), while raising the price target from $170 to $215.
Morgan Stanley: Maintaining Palantir Technologies' (PLTR) rating at "market-weighted", while raising the price target from $155 to $205.
B of A Securities: Maintaining a “buy” rating on Palantir Technologies (PLTR), while raising the price target from $215 to $255.
Piper Sandler: Maintaining Palantir Technologies' (PLTR) rating at "overweight", while raising the price target from $201 to $225.
Truist Securities: Maintaining a "Sell" rating on PayPal Holdings PayPal Holdings Inc(PYPL.US) , while raising the target price from $65 to $66.
JP Morgan: Maintaining Qualcomm's ( QUALCOMM Incorporated(QCOM.US) ) rating at "overweight", while raising the price target from $200 to $210.
First Coverage
B. Riley Securities: Initial rating for Antalpha Platform Holding ( Antalpha Platform Holding(ANTA.US) ) at "Buy", with a target price of $14.
Maxim Group: Initial rating for Arrive AI ( Arrive AI(ARAI.US) ) stock at "Buy", with a target price of $12.
HC Wainwright & Co.: Initial rating for Can-Fite BioPharma Ltd. ( Can-Fite BioPharma Ltd. Sponsored ADR(CANF.US) ) at "Buy", with a target price of $2.5.
B. Riley Securities: Initial rating for Phoenix Education ( Phoenix Education Partners, Inc.(PXED.US) ) stock at "Buy", with a target price of $60.
Mizuho: Qnity Electronics ( Quintiles Transnational Holdings, Inc.(Q.US) ) initial rating at "outperform", with a price target of $110.
Stephens & Co.: Initial rating for Twist Bioscience ( Twist Bioscience(TWST.US) ) at "overweight", with a target price of $41.
reduction
Piper Sandler: Maintaining Alerus Financial(ALRS.US) Financial's rating at "neutral", while lowering the price target from $25.5 to $24.
Deutsche Bank: Downgraded Alvotech ( Alvotech Ordinary Shares(ALVO.US) ) to "Hold", with a price target cut from $14 to $8.
Keefe, Bruyette & Woods: Maintaining Aon ( Aon plc(AON.US) ) rating at "Outperform Market", while lowering the price target from $428 to $410.
Scotiabank: Maintaining AvalonBay Communities ( AvalonBay Communities, Inc.(AVB.US) ) rating at "In-Sector Match", while lowering the price target from $215 to $193.
Truist Securities: Downgraded Dennis ( Denny's Corporation(DENN.US) ) to "Hold", while maintaining the price target at $6.
B of A Securities: Reduced its rating on DraftKings ( DraftKings(DKNG.US) ) to "neutral", with a price target cut from $48 to $35.
HC Wainwright & Co.: Maintaining Ur-Energy's ( Ur-Energy Inc.(URG.US) ) rating at "Buy", while lowering the price target from $2.7 to $2.6.
HC Wainwright & Co.: Maintaining Energy Fuels ( Energy Fuels Inc.(UUUU.US) ) rating at "Buy", while lowering the target price from $27.5 to $26.75.
Piper Sandler: Maintain Vertex's rating ( Vertex(VERX.US) ) at "Overweight", while lowering the target price from $42 to $32.
Needham: Maintain Vertex's rating ( Vertex(VERX.US) ) at "Buy", while lowering the target price from $40 to $30.
Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.